International Workshop on CLL 2025

Real-world impact of atrial fibrillation (AFib) on cardiovascular (CV) outcomes and healthcare resource utilization (HCRU) in patients with chronic lymphocytic leukemia (CLL)

Real-world treatment survival outcomes for zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among treatment-naïve patients with chronic lymphocytic leukemia (CLL) in the United States

Bruton tyrosine kinase (BTK) degrader BGB-16673 in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies: Results from the phase 1 CaDAnCe-101 study

BGB-16673, a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A phase 1 CaDAnCe-101 study update

Updated safety and efficacy of all‑oral sonrotoclax + zanubrutinib in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including patients with del(17p)/TP53

First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax and zanubrutinib achieves undetectable minimal residual disease rates of >90%, including in patients with del(17p)/TP53

Long-term follow-up for safety and efficacy of zanubrutinib in elderly (≥80 Years) treatment‑naïve CLL/SLL patients, including those with del(17p): Subgroup analysis from the SEQUOIA trial

Zanubrutinib vs ibrutinib in treatment-naive chronic lymphocytic leukemia (CLL): Implications for interpreting fixed-duration treatment outcomes from CLL17

A longitudinal analysis of patients with CLL/SLL with impaired health-related quality of life scores at baseline who were treated with zanubrutinib versus ibrutinib: A post hoc analysis of ALPINE